Hypothesis

Senescent cells exhibit a spectrum of SASP profiles that are shaped not only by the senescence trigger but also by the metabolic state of the cell. Recent work shows CD36 is rapidly upregulated upon senescence and initiates NF‑κB‑dependent cytokine production via amyloid‑beta signaling [2]. Parallel data indicate that mitochondrial dysfunction—low NAD+/NADH, reduced SIRT3/SIRT5, and Complex I impairment—amplifies SASP by suppressing AMPK and activating mTOR [3]. The SenNet consortium has further demonstrated that these mechanisms operate differently across tissues, producing context‑dependent SASP signatures [1).

Core proposition: In a given tissue, CD36‑mediated amyloid‑beta signaling acts as a molecular switch that determines whether the SASP skews toward a pathological, chronic inflammatory phenotype or a transient, repair‑supportive phenotype. This switch is modulated by the intracellular NAD+/SIRT3 axis; boosting NAD+ and SIRT3 activity flips the switch toward the reparative SASP without abolishing CD36 signaling entirely.

Mechanistic reasoning

1. CD36 as a scaffold for amyloid‑beta‑dependent NF‑κB activation – Amyloid‑beta binds CD36, triggering a Src‑family kinase cascade that sustains IKK activity. This pathway is fast‑acting and drives early SASP cytokines (IL‑6, IL‑8, CCL2).
2. NAD+/SIRT3 modulates the kinase scaffold – SIRT3 deacetylates and inhibits Src family kinases (e.g., Fyn) and also deacetylates Complex I subunits, improving electron flux and raising NAD+. When SIRT3 activity is high, Src kinase activity drops, weakening the CD36‑amyloid‑beta signal and shifting NF‑κB output toward a lower‑amplitude, more transient transcriptional program.
3. Tissue‑specific expression of CD36 regulators – SenNet data show variable expression of CD36 co‑receptors (e.g., TLR4, integrin αVβ3) and NAD+ biosynthetic enzymes (NAMPT, NAPRT) across organs. Consequently, the same CD36 level yields different SASP outputs depending on the local NAD+/SIRT3 tone.
4. Sex‑specific hormonal influence – Estrogen enhances NAMPT transcription, while testosterone can suppress SIRT3 activity. This provides a mechanistic basis for observed sex differences in senolytic responses.

Testable predictions

• Prediction 1: In human fibroblasts derived from skin and lung, pharmacological inhibition of CD36 (using sulfo-N-succinyl oleate) will reduce IL‑6 and CCL2 secretion by ~70% but will not affect VEGF‑A release, which is associated with angiogenic repair.
• Prediction 2: Treating the same cells with an NAD+ precursor (nicotinamide riboside) plus a SIRT3 activator (honokiol) will lower the CD36‑dependent NF‑κB p65 phosphorylation by ~50% while preserving or modestly increasing VEGF‑A and HGF secretion.
• Prediction 3: Combining low‑dose CD36 blockade with NAD+/SIRT3 activation will produce a SASP profile that shows reduced chronic inflammatory markers (IL‑1β, TNF‑α, MMP‑9) but unchanged or enhanced markers of tissue repair (VEGF‑A, PDGF‑BB, amphiregulin) compared with either intervention alone.
• Prediction 4: In a murine model of bleomycin‑induced lung fibrosis, female mice will exhibit a greater reduction in pathological SASP after NAD+/SIRT3 activation than males, correlating with higher lung NAMPT expression; ovariectomy will abolish this sex difference.

Experimental approach

1. In vitro: Isolate primary senescent cells from human skin, lung, and adipose tissue (using p16^INK4a^ reporter). Treat with: (a) vehicle, (b) CD36 inhibitor, (c) NAD+ precursor + SIRT3 activator, (d) combination. Measure SASP cytokines via multiplex ELISA, NF‑κB p65 phosphorylation by Western blot, and mitochondrial NAD+/NADH ratio by LC‑MS.
2. In vivo: Use aged male and female C57BL/6 mice subjected to bleomycin. Randomize to receive (i) CD36 inhibitor intratracheally, (ii) NAD+ booster orally, (iii) both, or (iv) control. Assess lung fibrosis (hydroxyproline content), SASP in bronchoalveolar lavage (IL‑6, TNF‑α, VEGF‑A), and senescence burden (p16^INK4a^ immunostaining) at 14 and 28 days.
3. Readouts: Primary outcome – shift in SASP ratio (pathological/repair) defined as (IL‑6+TNF‑α)/(VEGF‑A+PDGF‑BB). Secondary outcomes – fibrosis score, senescent cell count, sex‑specific differences.

Falsifiability

If CD36 inhibition combined with NAD+/SIRT3 activation fails to differentially affect pathological versus repair SASP (i.e., both classes of cytokines are reduced proportionally or unchanged), the hypothesis would be falsified. Likewise, if sex differences in response disappear after controlling for NAD+ levels but persist despite hormonal manipulation, the proposed hormonal‑NAD+/SIRT3 link would be refuted.

Implications

This hypothesis reframes senotherapeutic strategy: instead of globally suppressing SASP or ablating senescent cells, we aim to re‑program the SASP output by targeting the CD36‑amyloid‑beta signaling hub and tuning the mitochondrial NAD+/SIRT3 rheostat. Such a precision approach could retain beneficial senescence‑dependent tissue remodeling while mitigating chronic inflammation, addressing the outstanding challenges of tissue‑specific heterogeneity and sex‑specific responses highlighted in the recent literature.